Malignant Pancreatic Neoplasm — Trials

Malignant Pancreatic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 903
Recruiting: 504
Ph III recruiting: 46
Growth YoY: +21.9%
Industry share: 32%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.5%
Trials / 1,000 deaths: 18.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (516)

clinicaltrialsPublishedShowing 51–54 of 54 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01600807	OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas	withdrawn	Phase 1 / Phase 2	0	Dana-Farber Cancer InstituteOTHER	1	Jun 26, 2013	clinicaltrials
NCT01017822	Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer	withdrawn	Phase 1 / Phase 2	0	Radiation Therapy Oncology GroupNETWORK	0	Jun 24, 2013